Table 1
(continued)
Drug
Company
Known targets
Class Disease
Year
approved
Ribociclib
Novartis
CDK4/6
S/T
Breast cancer
2017
Ruxolitinib
Incyte
JAK1/2
NRY Myelofibrosis, polycythemia vera
2011
Sirolimus
Wyeth
FKBP/mTOR
S/T
Renal transplant, lymphangioleiomyomatosis
1999
Sorafenib
Onyx
VEGFR1/2/3, B-/RAF1, BRAF
V600E
, KIT, FLT3,
RET, p38, and PDGFRß
RY
Thyroid cancer, differentiated HCC, RCC
2005
Sunitinib
Pfizer
PDGFRα/β, VEGFR1/2/3, KIT, FLT3, CSF-1R,
AXL, RET
RY
RCC, GIST, pancreatic neuroendocrine tumors
2006
Temsirolimus Wyeth
FKBP12/mTOR
S/T
RCC
2007
Tofacitinib
Pfizer
JAK3
NRY Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis
2012
Trametinib
GSK
MEK1/2
T/Y
Melanoma
2013
Vandetanib
AstraZeneca
RET, EGFRs, VEGFRs, BEK, TIE2, EPHRs,
SRC family kinases
RY
Thyroid cancer, medullary
2011
Vemurafenib Genentech
BRAF
V600E
, RAF1
S/T
Melanoma (BRAF
V600+
)
2011
130
A. Moschopoulou et al.